The challenge of next-generation nanoparticles (NPs) includes limited
cellular uptake and loss by phagocytosis. General surface modification
of NPs potentially enhances evasion from phagocytosis. However, active
targeting and enhanced cellular uptake of nanoparticles are possible by
surface functionalisation with molecules that have selective affinity
for cancer cells. ROR1 is a cell surface receptor that is over-expressed
in cancer cells. Hence, its conjugate antibody could be a potential
surface functionalisation molecule. In the current study, anti-ROR1
antibody has been covalently attached to nanoparticles’ surface, thereby
imparting its active targeting potential. Physicochemical and in vitro
characterisations of the antibody-conjugated nanoparticles were
performed. Surface functionalisation of nanoparticles was confirmed by
scanning electron microscopy, isothermal calorimetry, and elemental
analysis. Additionally, biomarkers of metastasis and
epithelial-mesenchymal transition (EMT) were studied. Anti-ROR1 mAb
tagged nanoparticles further confirmed therapeutic efficacy against
colon cancer cells, SW480, thus, opening scope for further in vivo
studies.
Comparison Direct Synthesis of Hyaluronic Acid-Based Carbon Nanodots as Dual Active Targeting and Imaging of HeLa Cancer Cells
